Trials / Recruiting
RecruitingNCT06927570
A Study of HS-20122 in Patients With Advanced Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20122 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1,050 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-20122 | Intravenous (IV) administration of HS-20122 ; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression. |
Timeline
- Start date
- 2025-04-15
- Primary completion
- 2028-01-31
- Completion
- 2028-06-30
- First posted
- 2025-04-15
- Last updated
- 2026-01-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06927570. Inclusion in this directory is not an endorsement.